In a specialty memory clinic, patients treated with lecanemab over 14 months experienced manageable adverse events. ja.ma/45cpnXw Erik Musiek

Most viewed this week from JAMA Neurology: In a specialty memory clinic, patients treated with lecanemab over 14 months experienced manageable adverse events. ja.ma/3YNbf36

In this Editorial, JAMA Neurology Editor in Chief S Andrew Josephson reflects on 2024 accomplishments of the journal, discusses future plans, and acknowledges the contributions of the editorial team. ja.ma/44usFoQ

Venture capital investment in neurology companies has grown from 2000 to 2023, primarily focusing on pharmaceuticals and drug discovery. ja.ma/4keZfj8

Viewpoint: Although genetic therapies have shown significant promise, a centralized registry for systematic data sharing could enhance patient safety and improve therapeutic outcomes. ja.ma/43i1T0L

This case report describes a diagnosis of muscle infiltration of mycosis fungoides in a female aged 36 years with initial disease manifesting as pigmented skin patches. ja.ma/4kazEHX

Most viewed this week from JAMA Neurology: In a specialty memory clinic, patients treated with lecanemab over 14 months experienced manageable adverse events. ja.ma/43hcnxh

Individuals with more severe clinical Alzheimer disease symptoms than their biological stage often have additional pathologies. ja.ma/3H0b6TU

Among adults with episodic cluster headache, eptinezumab did not significantly reduce the frequency of episodic cluster headache attacks compared to placebo. ja.ma/3YW5Neq

Are blood thinners doing enough to prevent stroke in high-risk patients? Research explores the residual risk of recurrent stroke in patients with AF & suggests that treatment strategies are insufficient. bit.ly/3YWkBJY @jamaneuro and @esostroke #stroke #afib #ESOC25

Images in Neurology: A 52-year-old woman suddenly collapsed in a public place and was brought to a hospital by ambulance, presenting with a decreased level of consciousness. ja.ma/3ZizxCv

Individuals with more severe clinical Alzheimer disease symptoms than their biological stage often have additional pathologies, suggesting the need to evaluate non-AD biomarkers for accurate diagnosis. ja.ma/3ZrSB0Q

Individuals with more severe clinical Alzheimer disease symptoms than their biological stage often have additional pathologies, suggesting the need to evaluate non-AD biomarkers for accurate diagnosis. ja.ma/4jyxSjv

Despite a decrease in age-standardized rates, subarachnoid hemorrhage remains one of the most common cardiovascular and neurological causes of death and disability globally. #ESOC2025 European Stroke Org ja.ma/4mtU40w

In people with type 2 diabetes, both GLP-1RAs and SGLT2is were associated with decreased risk of Alzheimer disease and related dementias vs other glucose-lowering drugs, and no difference was observed between both drugs. ja.ma/4muRJm9

Most viewed this week from JAMA Neurology: Individuals with more severe clinical Alzheimer disease symptoms than their biological stage often have additional pathologies, suggesting the need to evaluate non-AD biomarkers for accurate diagnosis. ja.ma/4kkAUss

This case report describes cerebral white matter abnormalities from encephalitis caused by Angiostrongylus cantonensis in a 60-year-old woman. ja.ma/44tsfiy

This phase 2a clinical trial found that high-dose N-acetylcysteine (NAC) was safe, well tolerated, and reduced disease-associated biomarkers in patients with hereditary cystatin C amyloid angiopathy (HCCAA). ja.ma/4kcDJMq